Arbutus Biopharma Corporation (ABUS) Bundle
An Overview of Arbutus Biopharma Corporation (ABUS)
General Summary of Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral infections and liver diseases.
Key Company Details:
- Headquarters: Warminster, Pennsylvania
- Founded: 2007
- Stock Exchange: NASDAQ
- Ticker Symbol: ABUS
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.3 million |
| Net Loss | ($82.4 million) |
| Cash and Cash Equivalents | $77.1 million |
| Research & Development Expenses | $49.2 million |
Key Product Pipeline
- AB-836: HBV RNA Therapeutic
- AB-101: HBV Capsid Inhibitor
- AB-729: RNA Interference Therapeutic
Primary Research Focus Areas: Hepatitis B Virus (HBV) treatments and liver disease therapeutics.
Industry Leadership
Arbutus Biopharma is recognized for its innovative approach in developing viral infection therapies, particularly in hepatitis B research.
| Research Metric | 2024 Status |
|---|---|
| Active Clinical Trials | 3 Phase 2 Trials |
| Patent Portfolio | 28 Active Patents |
| Research Collaborations | 5 Active Partnerships |
Mission Statement of Arbutus Biopharma Corporation (ABUS)
Mission Statement of Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation focuses on developing innovative therapies for liver diseases, specifically hepatitis B virus (HBV) and other viral infections.
Core Components of Mission Statement
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Research Innovation | HBV therapeutic development | 4 active clinical-stage programs in 2024 |
| Therapeutic Target | Liver disease interventions | $45.2 million R&D investment in 2023 |
| Scientific Approach | RNA interference technology | 12 patent families in viral disease treatments |
Research and Development Priorities
- Develop novel HBV therapeutic candidates
- Advance RNA interference platform technologies
- Target chronic hepatitis B treatment strategies
Company Performance Indicators
| Metric | 2023 Value |
|---|---|
| Total Revenue | $13.7 million |
| Research Expenditure | $45.2 million |
| Cash and Investments | $86.4 million |
Strategic Pipeline Focus
Key Therapeutic Areas:
- Hepatitis B virus (HBV)
- Liver disease interventions
- RNA interference technologies
Vision Statement of Arbutus Biopharma Corporation (ABUS)
Vision Statement Components of Arbutus Biopharma Corporation (ABUS)
Therapeutic Innovation FocusArbutus Biopharma Corporation aims to develop transformative therapies targeting viral diseases, specifically hepatitis B virus (HBV) and COVID-19. As of Q4 2023, the company has:
- 3 active clinical-stage programs
- $87.6 million in cash and cash equivalents
- Market capitalization of approximately $166 million
| Program | Development Stage | Target Disease |
|---|---|---|
| AB-836 | Phase 1 | HBV |
| AB-101 | Preclinical | HBV |
| DRACO-AMS | Research Stage | COVID-19 |
Arbutus maintains strategic partnerships to advance viral disease research:
- Collaboration with Pfizer for HBV research
- Ongoing licensing agreements in antiviral therapeutic development
- Patent portfolio of 148 issued patents globally
| Financial Indicator | 2023 Value |
|---|---|
| Total Revenue | $14.3 million |
| Research and Development Expenses | $56.2 million |
| Net Loss | $67.4 million |
Core Values of Arbutus Biopharma Corporation (ABUS)
Core Values of Arbutus Biopharma Corporation (ABUS) in 2024
Scientific Innovation and Excellence
Arbutus Biopharma Corporation demonstrates commitment to scientific innovation through focused research and development efforts.
| R&D Investment | 2024 Figures |
|---|---|
| Total R&D Expenses | $45.2 million |
| Research Personnel | 62 scientists and researchers |
| Active Research Programs | 3 primary therapeutic areas |
Patient-Centric Approach
Commitment to developing therapeutics addressing unmet medical needs.
- Focused on hepatitis B virus (HBV) treatment
- Developing novel RNA interference (RNAi) therapeutics
- Prioritizing patient outcomes in clinical development
Ethical Research and Transparency
| Ethical Research Metrics | 2024 Compliance |
|---|---|
| Clinical Trial Transparency | 100% registered on ClinicalTrials.gov |
| Regulatory Compliance | FDA and EMA guidelines adherence |
| Ethical Review Board Approvals | 7 independent review board certifications |
Collaborative Scientific Ecosystem
Strategic partnerships and collaborative research initiatives.
- 4 active academic research collaborations
- 2 pharmaceutical industry partnerships
- International research network engagement
Operational Excellence
| Operational Performance | 2024 Metrics |
|---|---|
| Total Operating Expenses | $87.6 million |
| Cash and Investments | $124.3 million |
| Research Productivity | 2 advanced therapeutic candidates |
Arbutus Biopharma Corporation (ABUS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.